Truist Assigns Buy Rating to Genmab (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the 10 best large cap stocks under $30 with highest upside potential.

On May 27, coverage of Genmab A/S (NASDAQ:GMAB) was resumed by Truist analyst Gregory Renza. The analyst reduced the price target from $48 to $40 and assigned a Buy rating to the stock. He shared an optimistic view about the company following its shift towards a commercially focused business platform. This is backed by three key assets comprising around seven important readouts during 2026.

Pressmaster/Shutterstock.com

According to Renza, Rina-S and petosemtamab have the potential to be best- or first-in-class in ovarian cancer and HNSCC, respectively, while Epkinly’s DLBCL-2/-4 results are crucial for franchise expansion.

Back on April 30, H.C. Wainwright reduced the target price on Genmab A/S (NASDAQ:GMAB) from $40 to $38, leading to an adjusted upside potential in excess of 54%. The firm upheld its Buy rating on the shares.

Based on Pfizer’s MagnetisMM-5 trial outcomes, the firm anticipates a strong probability that, among physicians, Elrexfio will be favored over dexamethasone in treating relapsed or refractory multiple myeloma patients who have undergone at least one prior line of therapy.

Genmab A/S (NASDAQ:GMAB) is a biotechnology company based in Denmark that is engaged in developing antibodies and related products to cure cancer and other diseases. The company markets various cures for adults, including EPKINLY, TEPKINLY, and Tivdak.

While we acknowledge the risk and potential of GMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GMAB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1